HIV-1 remission following single CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

  • Daniela Ovadia — Agenzia Zoe
  • Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Key messages

  • New treatment strategies, based on preventing the expression of the CCR5 co-receptor, might eliminate HIV altogether.
  • The HIV-1 remission in the so-called “Berlin patient”, 10 years ago, was not isolated.
  • For the remission of HIV infection, a single CCR5Δ32/Δ32 allo-HSCT may be sufficient.

The only documented case of sustained HIV remission is the so-called “Berlin patient”, 10 years ago, who received 2 allo-HSCT using CCR5Δ32/Δ32 cells to treat his acute myeloid leukaemia with total body irradiation given with each HSCT. This new study reports a HIV remission with a less aggressive and toxic approach.

The HIV-1-infected adult was diagnosed in 2003, receiving antiretroviral therapy since 2012. In 2015, he received allo-HSCT for treatment of aggressive Hodgkin’s lymphoma (diagnosed in 2012), refractory to first-line chemotherapy and a number of salvage regimens. The donor was, as the “Berlin patient”, homozygous for CCR5Δ32. The 32-base pair deletion prevents CCR5 expression rendering these cells resistant to infection with HIV variants utilising the CCR5 co-receptor. As a result, host genotype was CCR5wt/wt before allo-HSCT (compared to the heterozygous CCR5WT/Δ32 genotype observed in the “Berlin Patient”), and became CCR5Δ32/Δ32 after transplant, with loss of CCR5 surface expression from circulating CD4 and CD8 T cells.

Antiretroviral therapy was maintained post-HSCT and was interrupted 16 months after transplantation. HIV-1 remission has been maintained through a further 18 months. Regular plasma viral load, weekly for the first 3 months and then monthly thereafter, was performed. These tests confirmed that plasma HIV-1 RNA has been undetectable at less than 1 copy per millilitre along with undetectable HIV-1 DNA in peripheral CD4 T lymphocytes.

Quantitative viral outgrowth assay from peripheral CD4 T lymphocytes showed no reactivatable virus using a total of 24 million resting CD4 T cells.

CD4 T cells isolated from peripheral blood post-transplant did not express CCR5. Indeed, cells were only susceptible to CXCR4-tropic virus ex vivo.

Analyses of both antibody and T cell responses were undertaken in order to further investigate the absence of persistent HIV-1 infection and antigenic stimulation. Both are highly reminiscent of observations in the “Berlin patient”.

Likewise in this study, the “Berlin patient” was CCR5-tropic HIV-1 infection and received of a CCR5Δ32/Δ32 transplant, but it was unclear which treatment or patient parameters contributed the most to HIV remission: either 2 allo-HSCT or 2 total body irradiation in conjunction with cyclophosphamide as the conditioning regimen. Although at 18 months post-treatment interruption it is premature to conclude that this patient has been cured, data suggest that single allo-HSCT with homozygous CCR5Δ32 donor cells may be sufficient to achieve HIV-1 remission with reduced intensity conditioning, in this case consisting of chemotherapy agents.